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A group of post-natal neurodevelopmental disorders collectively referred to as MeCP2 disorders are caused
by aberrations in the gene encoding methyl-CpG-binding protein 2 (MECP2). Loss of MeCP2 function causes
Rett syndrome (RTT), whereas increased copy number of the gene causes MECP2 duplication or triplication
syndromes. MeCP2 acts as a transcriptional repressor, however the gene expression changes observed in
the hypothalamus of MeCP2 disorder mouse models suggest that MeCP2 can also upregulate gene
expression, given that the majority of genes are downregulated upon loss of MeCP2 and upregulated in its
presence. To determine if this dual role of MeCP2 extends beyond the hypothalamus, we studied gene
expression patterns in the cerebellum of Mecp2-null and MECP2-Tg mice, modeling RTT and MECP2 dupli-
cation syndrome, respectively. We found that abnormal MeCP2 dosage causes alterations in the expression
of hundreds of genes in the cerebellum. The majority of genes were upregulated in MECP2-Tg mice and
downregulated in Mecp2-null mice, consistent with a role for MeCP2 as a modulator that can both increase
and decrease gene expression. Interestingly, many of the genes altered in the cerebellum, particularly
those increased by the presence of MeCP2 and decreased in its absence, were similarly altered in the hypo-
thalamus. Our data suggest that either gain or loss of MeCP2 results in gene expression changes in multiple
brain regions and that some of these changes are global. Further delineation of the expression pattern of
MeCP2 target genes throughout the brain might identify subsets of genes that are more amenable to manipu-
lation, and can thus be used to modulate some of the disease phenotypes.
INTRODUCTION
MECP2, the gene that encodes methyl-CpG-binding protein 2,
is located on chromosome Xq28. MECP2 mutations and copy
number variations cause a number of neurodevelopmental
disorders including Rett syndrome (RTT, MIM # 312750),
autism, X-linked mental retardation and the MeCP2 dupli-
cation/triplication syndromes (1–6). RTT primarily affects
females at a frequency of 1:10000 live births and is char-
acterized by a period of cognitive regression after a 6–12
months period of apparently normal development (7). The
phenotype of affected girls includes stereotypic hand move-
ments, severe mental retardation with loss of language,
seizures and microcephaly. In addition, affected individuals
display autism-like behaviors, anxiety, breathing irregularities,
sleep disturbances and autonomic dysfunction (8). MECP2
mutations can be detected in up to 96% of girls with classic
RTT, and include nonsense, missense and frameshift
mutations, as well as large deletions (9,10). The fact that trun-
cating mutations and early nonsense mutations cause RTT
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of MeCP2. Given that affected females are mosaic for MECP2
mutant and wild-type (WT) alleles, it is not surprising that
males hemizygous for MECP2 mutations are born with
severe infantile encephalopathy and die early (11). Hypo-
morphic alleles (missense mutations and late truncating
mutations) are associated with mental retardation and other
neuropsychiatric features in males. These mutations,
however, hardly cause a phenotype in mosaic carrier females
(12,13). Different mouse models resulting in either a null
allele or Mecp2 truncating mutations recapitulate RTT-like
phenotypes (14–16).
Increased dosage of MECP2 is associated with a distinct
neurological phenotype as well. Males with functional disomy
of chromosome Xq28, in the region spanning MECP2,
present with hypotonia, mental retardation and seizures,
whereas females carrying the duplication have mild psychiatric
symptoms owing to favorable X-chromosome inactivation
(XCI) patterns (Ramocki, Tavyev and Zoghbi, unpublished
data). Although the size of the duplication varies among differ-
ent patients and includes several genes, the minimal critical
region in all of the affected cases includes MECP2. Transgenic
mice expressing either 2X or 3X MeCP2 levels from the
endogenouspromoter(MECP2-Tg)showsigniﬁcantneurologi-
cal impairment, including motor dysfunction, seizures and
stereotypic behaviors (17). The data from MECP2-Tg mice
provide evidence that it is the duplication of MECP2 on
chromosome Xq28 that causes the abnormal neurological
phenotypes in human patients. Neurophysiological studies on
Mecp2-null and MECP2-Tg mice have demonstrated that loss
and gain of the protein have opposite effects on the number of
synapses in glutamatergic neurons (18). These ﬁndings,
together with data showing opposite expression patterns of
the same genes in Mecp2-null and MECP2-Tg mice (19),
support the conclusion that MECP2 duplication causes
disease by a gain of function (hyperfunction) mechanism.
Previous studies showed that MeCP2 acts as transcriptional
repressor by recruiting histone deacetylases to DNA contain-
ing methylated cytosines (20,21). Thus, it was expected that
girls with RTT, as well as mouse models of RTT, would
have an overexpression of genes due to loss of MeCP2 func-
tion. However, only a handful of MeCP2 target genes have
been identiﬁed. Transcriptional proﬁling studies using whole
brain from Mecp2-null mice revealed only subtle gene
expression changes (22), and studies investigating cerebellar
gene expression changes identiﬁed very few alterations that
did not withstand a correction for false discovery rate (FDR)
(23). A recent study proﬁling three different brain regions in
Mecp2-null mice (cortex, midbrain and cerebellum) found a
handful of signiﬁcant gene expression changes after correcting
for FDRs (24). Furthermore, the exact effect of MeCP2 on the
handful of putative targets was often unclear. For example,
whereas lack of MeCP2 was associated with increased levels
of brain-derived neurotrophic factor (Bdnf) in neuronal cell
cultures (25,26), in vivo studies revealed that BDNF protein
levels were actually reduced in brains of Mecp2-null mice
(27), and that Bdnf appears to be activated by MeCP2 in
mouse models of MeCP2 disorders (19).
Recently we explored whether some phenotypes of RTT
can be attributed to hypothalamic dysfunction. To this end,
we analyzed hypothalamic gene expression patterns in
Mecp2-null and MECP2-Tg mice. To our surprise, we found
thousands of signiﬁcant gene expression changes in the hypo-
thalamus. Even more interestingly, we found that most of the
altered genes were downregulated in Mecp2-null and upregu-
lated in MECP2-Tg mice. These results provided new insight
about MeCP2 function and suggested that MeCP2 might actu-
ally act as a transcriptional modulator that can both activate
and repress gene expression (19). Furthermore, a recent
study using chromatin immunoprecipitation (ChIP)–chip
analysis found that MeCP2 associates more frequently with
activated promoters (28). The ﬁnding that the expression of
2582 genes was altered in the hypothalamus, in contrast to a
handful of genes from whole brain, raised at least two possibi-
lities: ﬁrst, that these changes are speciﬁc to the hypothalamus
and secondly, that investigating a discrete brain region (rather
than whole brain) is a good strategy to uncover candidate
MeCP2 target genes. Because hypothalamic dysfunction
does not solely explain the complex phenotypes observed in
MeCP2 disorders, we proposed that gene expression altera-
tions do occur in other brain regions but that they might be
difﬁcult to detect because they are subtle. Hence, we chose
to investigate gene expression changes in other brain regions
in mouse models of MeCP2 disorders, and to compare the
patterns across regions.
To this end, we evaluated gene expression alterations result-
ing from MeCP2 dysfunction in the cerebellum. We found that
indeed MeCP2 affects the expression of hundreds of genes in
the cerebellum. Moreover, using quantitative reverse tran-
scriptase–PCR (QRT–PCR) and in situ hybridization (ISH),
we found that several of the gene alterations observed in
mouse models of MeCP2 disorders are not region-speciﬁc,
but are altered in two brain regions demonstrating that
MeCP2 has both global and region-speciﬁc effects on neuronal
gene expression.
RESULTS
Cerebellar gene expression changes in mouse models
of MeCP2 disorders
To investigate the effect of MeCP2 on gene expression in the
cerebellum, we analyzed cerebellar RNA using a microarray
platform that utilizes multiple probes along the different
exons of each gene (Affymetrix GeneChip mouse exon 1.0
ST array). The use of these arrays potentially enables reliable
detection of even small fold changes due to the existence of
multiple probes for most transcripts. We analyzed RNA
extracted from whole cerebella of ﬁve FVB MECP2-Tg
male mice (17) and their WT littermates, and ﬁve B6C57
(N7) Mecp2-null male mice (14) and their WT littermates, at
6 weeks of age. MECP2-Tg mice have increased expression
of human MECP2, whereas Mecp2-null male mice lack
MeCP2 protein. We studied the expression proﬁles in male
mice to avoid the confounding effect of variable XCI patterns
in females. Using a FDR-corrected P-value ,0.05 and a fold
change cutoff of +0.2, we found that 1180 genes are altered
in cerebella of MECP2-Tg mice compared with WT, whereas
1102 genes are altered in cerebella of Mecp2-null mice
compared with WT (Fig. 1).
2432 Human Molecular Genetics, 2009, Vol. 18, No. 13In order to conﬁrm the microarray results and to obtain an
independent measurement of fold changes between mutants
and controls, we used QRT–PCR. For these analyses, we
used cerebellar RNA from an independent set of MECP2-Tg
mice, Mecp2- null mice and their WT littermate controls.
For each animal, we tested 31 genes using one probe per
gene. We were able to conﬁrm alterations in 87% of the
genes tested in MECP2-Tg mice and in 68% of the genes
tested in Mecp2-null mice (P , 0.05) (Table 1). The fold
changes detected by QRT–PCR in both models were similar
to those observed for the microarray data; typically 1.2–
2-fold in either direction. The changes were, in general,
smaller in Mecp2-null compared with MECP2-Tg mice
based on both the microarray result and the QRT–PCR.
This difference may explain the lower conﬁrmation rates in
Mecp2-null mice. The magnitudes of fold changes detected
in the cerebellum were similar to those previously reported
in the hypothalamus (19). Interestingly, there was one excep-
tion where a gene was overexpressed in MECP2-Tg mice
18 times more than WT levels. The gene encodes proliferin
2( Prlf2), a prolactin-like protein also known as prolactin
family 2, subfamily c, member 2 (Prl2c2), and is located
8 Mb distal to the prolactin gene on mouse chromosome
13. The gene is reported to be rodent-speciﬁc and likely gen-
erated by duplication of the prolactin gene. Prlf2 expression
was not altered in hypothalami of MECP2-Tg or Mecp2-null
mice, thus alterations in expression of this gene are not
global in the brain (19). In order to conﬁrm the magnitude
of the observed fold change, we analyzed the expression of
Prlf2 by RNA ISH using sagittal brain sections from
6-week-old MECP2-Tg mice and their WT littermate controls,
and the images were pseudocolored using the Celldetekt pro-
tocol to determine the relative expression level on a per cell
basis (29) (Fig. 2A). To quantify the expression levels, the
total number of Prlf2-expressing cells was counted throughout
the cerebellum from two to three mice per genotype. We found
that there is 11 times more Prlf2 expression in cerebellar cells
of MECP2-Tg mice compared with WT (P , 0.004) (Fig. 2B).
Although this gene does not exist in humans, the magnitude of
the fold change seen in this case demonstrates that MeCP2
dysfunction can lead to marked alterations in the expression
of select transcripts.
Gain and loss of MECP2 have opposite effects on multiple
transcripts and most are increased by gain of MeCP2
Given that MeCP2 was originally identiﬁed as a transcrip-
tional repressor (21) one would expect that overexpression
of MeCP2 will result in reduced expression of multiple
genes, whereas loss of MeCP2 will lead to overexpression of
target genes. However, consistent with recent ﬁndings in the
hypothalamus (19), we found that 64% of the genes altered
in MECP2-Tg mice were upregulated compared with WT
and that 74% of the genes altered in Mecp2-null mice were
downregulated compared with WT (Fig. 1).
We found that 583 genes were commonly altered in cere-
bella of both MECP2-Tg and Mecp2-null mice (Fig. 3A).
Most of these genes (95%) were altered in an opposite
direction in the two models, and the majority (75%) was upre-
gulated by the presence of MeCP2 and downregulated by lack
of MeCP2 (Fig. 3B, Supplementary Material, Tables S1 and
S2). On the other hand, 597 genes were only misregulated in
MECP2-Tg cerebella, and 519 genes were only misregulated
in Mecp2-null cerebella (Supplementary Material, Tables S3
Table 1. Conﬁrmation of cerebellar gene expression changes by QRT–PCR
in MECP2-Tg and Mecp2-null mice compared with WT littermate controls
(P , 0.05)
Gene MECP2-Tg Mecp2-null
Fold change P-value Fold change P-value
Prlf2 18.23 4.42E206 21.68 3.85E202
Rcor2 2.97 4.85E205 21.03 NS
Gdf11 2.25 3.64E205 22.07 9.07E206
Alpk2 2.13 3.59E203 22.36 1.06E203
Cyp4f15 2.07 3.01E203 21.39 2.80E202
Gpr26 1.90 5.93E203 21.75 3.30E202
Apba2bp 1.79 9.27E204 21.46 7.43E203
Gpr165 1.68 8.29E205 21.52 3.09E204
Nxph4 1.63 7.22E203 21.58 4.06E204
Gprk5 1.62 9.34E204 21.45 2.05E204
Hdc 1.60 6.99E203 21.27 1.87E202
Gamt 1.59 2.33E203 21.37 1.71E202
Paqr6 1.55 2.73E203 21.18 NS
Ephb6 1.53 1.90E203 21.16 NS
Cacng4 1.46 2.96E203 21.35 1.83E203
Erbb3 1.43 9.75E204 21.65 2.23E203
Zcchc12 1.43 NS 21.21 NS
Tgfb1 1.41 1.30E202 21.18 7.71E203
Gabra3 1.39 2.14E203 21.34 3.37E202
Coch 1.38 1.84E202 21.18 NS
Pcsk1 1.30 2.90E202 21.39 1.01E202
Ngef 1.18 NS 21.61 4.52E202
Lrp1b 21.62 2.37E202 1.15 3.04E202
Cep72 21.22 4.55E202 1.29 1.12E202
Robo2 21.25 NS 1.20 NS
Pcolce2 21.28 3.99E203 1.39 NS
Robo1 21.33 9.40E203 1.24 1.13E202
Auts2 21.36 NS 1.33 NS
Pygm 21.63 5.24E205 1.36 1.38E202
Ntng1 21.77 1.99E203 1.13 NS
Kcnh7 21.97 2.76E204 1.20 NS
NS, not signiﬁcant; P   0.05.
Figure 1. Studies of cerebellar gene expression changes in MECP2-Tg and
Mecp2-null mice. Most of the genes altered in both mouse models are upregu-
lated in the presence of MeCP2 and downregulated in its absence.
Human Molecular Genetics, 2009, Vol. 18, No. 13 2433and S4). Interestingly, a very small proportion of the 583
genes (32) was altered in the same direction in the two
models (Supplementary Material, Tables S5 and S6). If
indeed the overexpression and the lack of MeCP2 have oppo-
site molecular effects, it may be that the genes that are
uniquely altered in each model, or that are altered in the
same direction in both models, represent secondary effects
due to neuronal dysfunction. These results imply that
MeCP2 is likely to act as a positive regulator of gene
expression in the cerebellum as well. As the expression analy-
sis cannot differentiate primary versus secondary changes
associated with MeCP2, it is still possible that MeCP2 acts
primarily as a repressor and that the main activation effect
in the transgenic mice cerebella is a secondary change gener-
ated by repression of a primary MeCP2 target. However, our
analysis did not reveal a bona ﬁde repressor that is downregu-
lated by MeCP2 and that can potentially cause a secondary
repression in Mecp2-null mice and a secondary activation in
MECP2-Tg mice.
In order to distinguish primary versus secondary MeCP2
target genes, we performed ChIP on cerebella from three
MECP2-Tg, Mecp2-null and WT mice. We found that
MeCP2 binds to the promoter regions of the activated target
Gpr26 and the repressed target Lrp1b (Fig. 4). Gpr26
Figure 2. RNA ISH demonstrates that Prlf2 is highly upregulated in MECP2-Tg cerebellum compared with WT (A). Prlf2-expressing cells were counted on
sections throughout the cerebellum (B)(  P , 0.004).
2434 Human Molecular Genetics, 2009, Vol. 18, No. 13encodes the G protein-coupled receptor (GPCR) 26, a consti-
tutively active orphan GPCR that is predominantly expressed
in the brain (30) and that has been shown to be downregulated
in glioblastoma (31). In the hypothalamus, Gpr26 was
activated by MeCP2 (upregulated in MECP2-Tg and downre-
gulated in Mecp2-null mice) (19). Lrp1b encodes the low-
density lipoprotein-related protein 1B (deleted in tumors). It
is expressed in the adult brain and was originally described
as a putative tumor suppressor in lung cancer cells. In
addition, it can bind to amyloid precursor protein (APP) and
decrease its processing to amyloid beta peptides (32). Lrp1b
is also repressed by MeCP2 in the hypothalamus (19).
Gene ontology analysis revealed higher similarity in
function and structure of genes that are upregulated
than those downregulated by MeCP2
We analyzed the gene ontology (GO) of the transcripts altered
in cerebella of models of MeCP2 disorders. The analysis
included only the genes that were altered in both
MECP2-Tg and Mecp2-null mice in opposite directions. Inter-
estingly, on the basis of all of the categories (cellular com-
ponent, biological process and molecular function), we
found that genes upregulated by MeCP2 are more likely to
be associated with speciﬁc processes and GO terms compared
with downregulated genes, suggesting an increased structure
or function relatedness between putatively activated target
genes compared with repressed genes (Fig. 5A–C). Some of
the categories speciﬁcally enriched in the list of upregulated
targets include: transmission of nerve impulse, dendrite
development and neuroblast proliferation.
Multiple gene expression changes in MeCP2 disorder
mouse models are common to the hypothalamus
and cerebellum
To determine if the altered genes are region-speciﬁc, we com-
pared the changes observed in the cerebellum to those pre-
viously reported in the hypothalamus (19). We found that
out of the 583 genes commonly altered in cerebella of both
MECP2-Tg and Mecp2-null mice, 244 genes were also
altered in the hypothalamus, suggesting that MeCP2 regulates
or affects the expression of some genes in both brain regions.
The degree of overlap between altered genes was signiﬁcantly
higher for those that are misregulated in opposite directions in
the MECP2-Tg and Mecp2-null mice than for genes altered
only in one disease model (Fig. 6). This ﬁnding suggests
that genes that are inversely altered in both models may be
more relevant to the disease in terms of their broader effect,
possibly as a consequence of being direct targets of MeCP2.
Moreover, we found that the degree of overlap between cer-
ebellum and hypothalamus is higher (49%) for genes that
are predicted to be activated in the presence of MeCP2 com-
pared with genes that are predicted to be repressed (21%).
This is consistent with the higher rate of activated genes and
might suggest that among the activated genes there are candi-
dates that may play an important role in the pathogenesis of
MeCP2 disorders. GO analysis of genes misregulated in both
the cerebellum and hypothalamus revealed that for all the cat-
egories (cellular component, biological process and molecular
function), genes upregulated by MeCP2 are associated with
speciﬁc GO terms, compared with those downregulated by
MeCP2 (Fig. 7A–C). In addition, we compared our gene
lists (Supplementary Material, Tables S1–S6) to those from
various published studies (33–37), and found very little
overlap between these genes, and the direction of change
was not always consistent (Supplementary Material,
Table S7). This is not surprising given that these studies
used different analysis methods and were performed on differ-
ent tissues: post-mortem brain tissue from RTT patients (33),
Figure 3. Cerebellar gene expression changes common to both MECP2-Tg
and Mecp2-null mice. (A) The majority of genes altered in both mouse
models (95%) show opposite direction of change, usually activation. (B)
Heatmap showing cerebellar gene expression proﬁles in MECP2-Tg and
Mecp2-null mice. Yellow and blue colors indicate increased and decreased
expression, respectively, relative to WT. Each column represents one RNA
sample from each genotype, and each row represents one gene. Expression
levels are depicted according to the color scale at the bottom (FDR-corrected
P , 0.05).
Figure 4. MeCP2 binds to the promoter regions of an activated (Gpr26) and a
repressed (Lrp1b) target gene. ChIP with antibody to MeCP2 detects MeCP2
binding to the promoter region of two novel targets. QPCR values were nor-
malized to the input and plotted as relative enrichment over Mecp2-null
(n ¼ 3,  P , 0.05).
Human Molecular Genetics, 2009, Vol. 18, No. 13 2435single cell-derived WT and mutant MECP2 expressing ﬁbro-
blast clones (34), patient T lymphocytes (35), Mecp2-null
mouse whole brain (36) and SH-SY5Y neuronal cells
induced to differentiate and in which MeCP2 binding to
DNA was blocked (37).
DISCUSSION
MeCP2 disorders comprise a wide variety of neurodevelop-
mental disorders including RTT, MeCP2 duplication/
triplication syndromes and other isolated neurological pheno-
types such as mental retardation, juvenile onset schizophrenia
and autism. Several studies have pursued the identiﬁcation of
MeCP2 targets or gene expression changes in Mecp2-null
mice. Very few signiﬁcant changes were detected if one is
to consider FDR correction in data analysis (22–24). Interest-
ingly, the use of hypothalamic RNA uncovered thousands of
gene expression changes in mouse models of MeCP2 disorders
(19). The majority of changes had a magnitude of less than +
1.5-fold, and only 2% of genes had changes in the 3–5-fold
range. This low magnitude of gene expression changes could
explain why one might need to use sensitive methods, such
as the exon arrays (with multiple probes per gene), to detect
gene expression differences. Although earlier attempts to
detect gene expression alterations in whole brain, cerebellum
and cortex of RTT mouse models only uncovered a few
target genes (23), the fact that cerebellar function is essential
for normal movement and coordination and because RTT
mouse models have widespread morphological changes in
the brain, including the cerebellum, (38), led us to evaluate
the patterns of cerebellar gene expression in mouse models
of MeCP2 disorders.
Our study detected hundreds of gene expression alterations
in the cerebella of both Mecp2-null and MECP2-Tg mice,
using a very stringent FDR-corrected P , 0.05. The majority
Figure 5. Gene ontology analysis performed on genes that are differentially expressed in cerebella of MECP2-Tg and Mecp2-null mice. Cellular component (A),
molecular function (B) and biological process (C) categories that differ signiﬁcantly between the genes activated by MeCP2 (yellow) and those repressed by
MeCP2 (blue) are plotted. The standardized scores (Z values) are presented on the x-axis, and signiﬁcance was determined by a Z-value of more than + 2
and a count of at least two genes. þve, positive; 2ve, negative; CNS, central nervous system; inﬂam., inﬂammatory; dep., dependent; transmem., transmem-
brane; EC, extracellular.
2436 Human Molecular Genetics, 2009, Vol. 18, No. 13of these changes demonstrated that there is transcriptional
repression (rather than derepression) in the absence of
MeCP2. As observed in the hypothalamus, the majority of
the fold changes in the cerebellum were small, with one excep-
tion being the change observed for Prlf2. A similar small mag-
nitude of change in MeCP2 target genes was also detected
using ISH studies (39,40); suggesting that MeCP2 modulates
gene expression and ﬁne-tunes levels of its target genes
rather than causing large fold changes. Although the fold
changes in gene expression are mostly 50% more or less
than WT, such changes are likely to be quite signiﬁcant func-
tionally. Human studies are teaching us that a 50% decrease or
increase in gene copy number is sufﬁcient to cause a variety of
neuropsychiatric disorders that have overlapping symptoms
Figure 5. Continued.
Human Molecular Genetics, 2009, Vol. 18, No. 13 2437with RTT and MeCP2 duplication syndrome. Interestingly, we
identiﬁed genes that are altered in both the cerebellum and the
hypothalamus. Furthermore, we found that the greatest overlap
in gene expression proﬁles between the brain regions occurred
with the group of genes that are activated rather than
repressed. The genes putatively activated by MeCP2 in both
the cerebellum and hypothalamus code for proteins involved
in neuronal development, synaptic transmission and neuro-
transmitter transport; processes that are potentially disrupted
in RTT and MeCP2 duplication syndrome, and could
account for some of the phenotypes observed in MeCP2 dis-
orders. Since MeCP2 is expressed in both brain regions, it is
not surprising that it affects the levels of some genes in both
regions. What is notable is that almost all of the gene
expression changes that occur in both brain regions share
directionality. We also compared our data with data generated
from other gene expression studies (see Supplementary
Material, Table S7). We found that six genes, Auts2, Enpp2,
Fxyd7, Gpr56, Plcb1 and Stx1a, are consistently altered in
our datasets and post-mortem RTT patient brain, and mutant
ﬁbroblasts and lymphocytes. This is quite interesting given
the functions of these genes. Gpr56 is disrupted in patients
with bilateral frontoparietal polymicrogyria, a disorder charac-
terized by developmental delay, mental retardation, motor
abnormalities, seizures and ataxia (41). Auts2 (autism suscep-
tibility candidate 2) is associated with severe mental
retardation with autistic features (42,43), and Stx1a is involved
in synaptic vesicle fusion. Although the number of genes
altered in the cerebellum (hundreds) was not as prominent
as in the hypothalamus (thousands), our study demonstrates
that MeCP2 levels affect the expression of hundreds of
genes in the cerebellum. Genes that are altered in
a region-speciﬁc manner in MeCP2 disorder mouse models,
probably represent genes with region-speciﬁc expression
and/or function. The fact that MeCP2-mediated gene
expression changes extend beyond the hypothalamus, raises
the possibility that genes commonly altered in more than
one brain region may be better candidates for future thera-
peutic strategies in MeCP2 disorders.
MATERIALS AND METHODS
Microarray data analysis
We used the Affymetrix Mouse Exon 1.0 ST microarray, which
carries 1.2 million probe sets that cover 1 million exon clusters,
withanaverageof40probespergene.Theexonarraydatawere
analyzed as previously described (19). Brieﬂy, raw data were
processed in the R statistical programming environment using
locally developed methods and the exonmap package. Robust
multichip average (RMA) normalization was applied, and sub-
sequently, linear models were calculated to analyze genotype
effects for each gene. Genomic annotations were obtained
from UCSC (http://genome.ucsc.edu). The normalized probe
level data were then averaged within each exon to produce
exon level data for each gene for each animal. A two-way
ANOVA with main effects for genotype and exonic region
was calculated for each gene. The ANOVA model was ﬁt
using weighted least squares analysis where the weights were
determined according to the probe counts within each exon.
Since separate WT littermates of different strains were used
in the Mecp2-null (C57BL/6J) and MECP2-Tg (FVB) exper-
iments, a separate linear model was estimated for each gene
in each strain (one ﬁt for each WT background). A linear con-
trast was calculated comparing the WT and mutant cross-exon
means for each gene. The cutoff rule for determining genes
regulated by MeCP2 was a fold change threshold of +0.2 in
both the MECP2-Tg and the Mecp2-null lists, and a linear
step up FDR of ,0.05 value for the T-statistic corresponding
to the linear contrast comparing each WT strain with its corre-
sponding mutant. The gene set determined by this fold change
and FDR multiplicity corrected cutoff, corresponds to a
median raw marginal P-value of 0.00015 for the underlying
T-statistics.
Post-processing of our gene lists was performed to deter-
mine their content using GO analysis. The GO vocabulary
was obtained from the GO website (9 January 2007 build),
and current mouse annotations were also downloaded. The
mouse exon array was mapped to entrez identiﬁers, and
these identiﬁers were mapped to the GO data structure using
the available annotations. Using our local ontology analysis
system (OntologyTraverser), we tabulated the genes annotated
at or below each GO node for the entire exon array. We then
used a hypergeometric sampling model to examine the statisti-
cal representation of each GO node for genes in our gene sets.
In order to make comparisons between sets, we took differ-
ences between the standardized scores determined for each
gene set. Because of the extreme overlapping structure of
the GO, many GO nodes report duplicate or redundant infor-
mation. To avoid this problem, we calculated the GO covari-
ance structure and used this estimate to compute de-correlated
GO scores.
Figure 6. Gene expression changes common to the cerebellum and hypothala-
mus. Groups 1–8 in the top panel are described in the lower panel. For
example, genes in Group 1 are upregulated in MECP2-Tg and downregulated
in Mecp2-null mice, 201 such genes are altered in both the cerebellum and
hypothalamus, and activated in the hypothalamus.
2438 Human Molecular Genetics, 2009, Vol. 18, No. 13Figure 7. Gene ontology analysis performed on genes that are differentially expressed in cerebella and hypothalami of MECP2-Tg and Mecp2-null mice. Cel-
lular component (A), molecular function (B) and biological process (C) categories that differ signiﬁcantly between the genes activated by MeCP2 (yellow) and
those repressed by MeCP2 (blue) are plotted. The standardized scores (Z-values) are presented on the x-axis, and signiﬁcance was determined by a Z-value of
more than + 2 and a count of at least two genes. CNS, central nervous system; inﬂam., inﬂammatory; transmem., transmembrane.
Human Molecular Genetics, 2009, Vol. 18, No. 13 2439Quantitative real-time RT–PCR
Total RNA was extracted from cerebella of 6-week-old male
mice using TRIzol reagent (Invitrogen Corporation, Carlsbad,
CA, USA), DNase I treated, and puriﬁed using the RNAeasy
mini kit according to the manufacturer’s protocol (Qiagen,
Valencia, CA, USA). Experiments were performed on three
to ﬁve mice of each genotype. cDNA was synthesized from
1 mg of RNA using the RT2 First Strand Kit (SuperArray Bio-
science Corporation, Frederick, MD, USA). Quantitative real-
time PCR reactions were performed on 10 ng of cDNA using
RT2 SYBR Green/ROX PCR master mix and commercially
available primers (SuperArray Bioscience Corporation). All
RNA samples were analyzed in triplicate and normalized rela-
tive to Gapdh levels.
Non-radioactive ISH
Sagittal sections from two to three mice of each geotype were
analyzed. Tissue preparation and automated ISH were per-
formed as previously described (44–46) and as described
online at http://www.genepaint.org/RNA.htm. Prlf2 antisense
probe was generated from a cDNA clone. The cDNA template
was ampliﬁed by PCR and used for in vitro transcription of
digoxygenin-labeled riboprobe. We performed quantitative
analysis of the ISH signal on sections spanning the cerebellum
using the Celldetekt protocol to determine cellular gene
expression levels (29).
ChIP
ChIP was performed as previously described (19). Cerebella
were dissected from three mice of each genotype at 6 weeks
of age and incubated in 1% formaldehyde for 10 min at
room temperature to cross-link DNA to associated proteins.
Chromatin was prepared and sheared to generate fragments
with an average length of 100–200 bp, as determined
empirically by agarose gel electrophoresis. For immunopreci-
pitation, 200 ml of chromatin was diluted 1:10 in ChIP dilution
buffer (Millipore Corporation, Billerica, MA, USA) and 1% of
the diluted sample was set aside for input. The sample was ﬁrst
pre-cleared with protein A Dynabeads (Invitrogen Corpor-
ation), then incubated overnight with protein A Dynabeads
that were pre-blocked with salmon sperm DNA and 5 mgo f
rabbit polyclonal anti-MeCP2 antibody (Millipore Corpor-
ation). Mock immunoprecipitation with 5 mg of non-speciﬁc
rabbit immunoglobulin G was included as a control. After
immunoprecipitation, the beads were washed sequentially at
room temperature with low salt buffer, high salt buffer, LiCl
buffer (Millipore Corporation) and TE buffer (10 mM Tris–
HCl pH 7.4, 1 mM EDTA pH 8.0). Elution was performed
twice in 250 ml of fresh elution buffer (1% SDS, 0.1 M
NaHCO3) for 15 min at room temperature. The eluates were
combined, the cross-links were reversed and DNA was recov-
ered by standard methods in 30 mlo f1 0m M Tris–HCl pH 8.0.
One microliter of DNA was used for each quantitative real-
time PCR. ChIP experiments were performed in triplicate,
and all quantitative real-time PCR experiments were
performed in triplicate. The quantitative real-time PCR
data were analyzed as previously described (19). Relative
proportions of immunoprecipitated DNA were determined on
the basis of the threshold cycle value and normalized to the
input. Primer and probe sequences used were as follows:
Lrp1b: Forward 50-TGGTGGCCCACAACTTTAATC-30;
Reverse 50-CCTGGGCATAGAACTCAGATCTTC-30; Probe
FAM-TCTGCCTCTGCATCCTGACTGCTG-BHQ; Gpr26:
Forward 50-TGTCTGGGCACCCTCATGT-30; Reverse 50-
CAGGTGGACTGGGTCAAGGT-30; Probe FAM-CCAGTG
CTGCTTGTCCCTGC-BHQ.
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